Acknowledgement
Supported by : Korea Health Industry Development Institute (KHIDI)
References
- Sellares J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012;12:388-99.
- Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9 Suppl 3:S1-155.
- Archdeacon P, Chan M, Neuland C, Velidedeoglu E, Meyer J, Tracy L, et al. Summary of FDA antibody-mediated rejection workshop. Am J Transplant 2011;11:896-906.
- Roberts DM, Jiang SH, Chadban SJ. The treatment of acute antibody-mediated rejection in kidney transplant recipients: a systematic review. Transplantation 2012;94:775-83.
- Chung BH, Yang CW. Current issues in the treatment of chronic antibody-mediated rejection in kidney transplantation. Hanyang Med Rev 2014;34:211-6.
- Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009;9:201-9.
- Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008;86:1754-61.
- Yang KS, Jeon H, Park Y, Jo IH, Kim JI, Moon IS, et al. Use of bortezomib as anti-humoral therapy in kidney transplantation. J Korean Med Sci 2014;29:648-51.
- De Sousa-Amorim E, Revuelta I, Diekmann F, Cofan F, Lozano M, Cid J, et al. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: a single-centre case series. Nephrology (Carlton) 2016;21:700-4.
- Lee J, Kim BS, Park Y, Lee JG, Lim BJ, Jeong HJ, et al. The effect of bortezomib on antibody-mediated rejection after kidney transplantation. Yonsei Med J 2015;56:1638-42.
- Lee HM, Jang IA, Lee D, Kang EJ, Choi BS, Park CW, et al. Risk factors in the progression of BK virus-associated nephropathy in renal transplant recipients. Korean J Intern Med 2015;30:865-72.
- Kim YJ, Jeong JC, Koo TY, Kwon HY, Han M, Jeon HJ, et al. Impact of combined acute rejection on BK virus-associated nephropathy in kidney transplantation. J Korean Med Sci 2013;28:1711-5.
- McGregor SM, Chon WJ, Kim L, Chang A, Meehan SM. Clinical and pathological features of kidney transplant patients with concurrent polyomavirus nephropathy and rejection-associated endarteritis. World J Transplant 2015;5:292-9.
- Nishio-Lucar A, Balogun RA, Sanoff S. Therapeutic apheresis in kidney transplantation: a review of renal transplant immunobiology and current interventions with apheresis medicine. J Clin Apher 2013;28:56-63.
- Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant 2003;3:653-64.
- Jordan SC, Vo AA, Peng A, Toyoda M, Tyan D. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006;6:459-66.
- Wan SS, Ying TD, Wyburn K, Roberts DM, Wyld M, Chadban SJ. The treatment of antibody-mediated rejection in kidney transplantation: an updated systematic review and meta-analysis. Transplantation 2018;102:557-68.
- Sautenet B, Blancho G, Buchler M, Morelon E, Toupance O, Barrou B, et al. One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial. Transplantation 2016;100:391-9.
- Woodle ES, Tremblay S, Driscoll J. Targeting plasma cells with proteasome inhibitors: principles from primates. J Am Soc Nephrol 2017;28:1951-3.
- Kim MG, Kim YJ, Kwon HY, Park HC, Koo TY, Jeong JC, et al. Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation. Nephrology (Carlton) 2013;18:820-6.
- Walsh RC, Alloway RR, Girnita AL, Woodle ES. Proteasome inhibitor-based therapy for antibody-mediated rejection. Kidney Int 2012;81:1067-74.
- Woodle ES, Shields AR, Ejaz NS, Sadaka B, Girnita A, Walsh RC, et al. Prospective iterative trial of proteasome inhibitorbased desensitization. Am J Transplant 2015;15:101-18.
- Diwan TS, Raghavaiah S, Burns JM, Kremers WK, Gloor JM, Stegall MD. The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo. Transplantation 2011;91:536-41.
- Gonzalez S, Escobar-Serna DP, Suarez O, Benavides X, Escobar-Serna JF, Lozano E. BK virus nephropathy in kidney transplantation: an approach proposal and update on risk factors, diagnosis, and treatment. Transplant Proc 2015;47:1777-85.
- Hodur DM, Mandelbrot D. Immunosuppression and BKV Nephropathy. N Engl J Med 2002;347:2079-80.
- Prince O, Savic S, Dickenmann M, Steiger J, Bubendorf L, Mihatsch MJ. Risk factors for polyoma virus nephropathy. Nephrol Dial Transplant 2009;24:1024-33.
- O'Leary JG, Samaniego M, Barrio MC, Potena L, Zeevi A, Djamali A, et al. The influence of immunosuppressive agents on the risk of de novo donor-specific HLA antibody production in solid organ transplant recipients. Transplantation 2016;100:39-53.
- Nickeleit V, Mihatsch MJ. Polyomavirus allograft nephropathy and concurrent acute rejection: a diagnostic and therapeutic challenge. Am J Transplant 2004;4:838-9.
- Wu D, Zhang MC, Chen JS, Li X, Cheng DR, Xie KN, et al. BK virus-associated nephropathy with plasma cell-rich infiltrates treated by bortezomib-based regimen. Exp Clin Transplant 2015;13:603-6.
- Everly MJ. A summary of bortezomib use in transplantation across 29 centers. Clin Transpl 2009;23:323-37.
- Cosio FG, Cattran DC. Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation. Kidney Int 2017;91:304-14.
- Blosser CD, Bloom RD. Recurrent glomerular disease after kidney transplantation. Curr Opin Nephrol Hypertens 2017;26:501-8.
- Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA, Traynor C, Flanagan M, Wong L, et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol 2014;9:46-53.
- Zand L, Lorenz EC, Cosio FG, Fervenza FC, Nasr SH, Gandhi MJ, et al. Clinical findings, pathology, and outcomes of C3GN after kidney transplantation. J Am Soc Nephrol 2014;25:1110-7.